PT Kimia Farma (Persero) Tbk (KAEF.JK)
IDR 600.0
(-0.83%)
IDR 600.0
(-0.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1223.64 Billion IDR | -209.28% |
| 2022 | 1019.74 Billion IDR | -35.36% |
| 2021 | 1391.47 Billion IDR | 50.46% |
| 2020 | 914.09 Billion IDR | 35.26% |
| 2019 | 695.94 Billion IDR | -28.31% |
| 2018 | 1161.03 Billion IDR | 45.64% |
| 2017 | 608.37 Billion IDR | 17.8% |
| 2016 | 492.86 Billion IDR | 20.27% |
| 2015 | 418.83 Billion IDR | 19.23% |
| 2014 | 379.72 Billion IDR | 16.53% |
| 2013 | 293.88 Billion IDR | -2.32% |
| 2012 | 304.81 Billion IDR | 35.53% |
| 2011 | 260.71 Billion IDR | 51.85% |
| 2010 | 146.19 Billion IDR | 46.68% |
| 2009 | 99.67 Billion IDR | 1.39% |
| 2008 | 98.3 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 61.64 Billion IDR | 108.32% |
| 2024 Q3 | -735.32 Million IDR | -101.33% |
| 2024 Q2 | 55.13 Billion IDR | -56.79% |
| 2023 Q4 | -1335.93 Billion IDR | -1685.33% |
| 2023 Q1 | 204.33 Billion IDR | -51.89% |
| 2023 FY | - IDR | -209.28% |
| 2023 Q2 | 189.71 Billion IDR | -7.15% |
| 2023 Q3 | 84.26 Billion IDR | -55.58% |
| 2022 Q3 | 286.65 Billion IDR | 3573.41% |
| 2022 FY | - IDR | -35.36% |
| 2022 Q4 | 424.71 Billion IDR | 48.16% |
| 2022 Q2 | 7.8 Billion IDR | -94.76% |
| 2022 Q1 | 149.06 Billion IDR | -35.35% |
| 2021 Q1 | 208.42 Billion IDR | -14.6% |
| 2021 Q4 | 230.56 Billion IDR | -56.3% |
| 2021 FY | - IDR | 50.46% |
| 2021 Q3 | 527.64 Billion IDR | 100.5% |
| 2021 Q2 | 263.16 Billion IDR | 26.26% |
| 2020 Q1 | 185.07 Billion IDR | 94.2% |
| 2020 FY | - IDR | 35.26% |
| 2020 Q2 | 261.82 Billion IDR | 41.47% |
| 2020 Q3 | 142.97 Billion IDR | -45.39% |
| 2020 Q4 | 244.04 Billion IDR | 70.69% |
| 2019 Q4 | 95.3 Billion IDR | -37.79% |
| 2019 Q1 | 122.61 Billion IDR | -62.65% |
| 2019 Q2 | 232.92 Billion IDR | 89.97% |
| 2019 Q3 | 153.18 Billion IDR | -34.23% |
| 2019 FY | - IDR | -28.31% |
| 2018 Q4 | 328.31 Billion IDR | 53.99% |
| 2018 Q2 | 165.17 Billion IDR | 20.93% |
| 2018 Q1 | 136.59 Billion IDR | -37.37% |
| 2018 FY | - IDR | 45.64% |
| 2018 Q3 | 213.2 Billion IDR | 29.08% |
| 2017 Q3 | 166.31 Billion IDR | 37.39% |
| 2017 Q4 | 218.09 Billion IDR | 31.13% |
| 2017 Q2 | 121.05 Billion IDR | 71.98% |
| 2017 Q1 | 70.38 Billion IDR | -60.78% |
| 2017 FY | - IDR | 17.8% |
| 2016 Q2 | 94 Billion IDR | 20.98% |
| 2016 FY | - IDR | 20.27% |
| 2016 Q4 | 179.48 Billion IDR | 28.27% |
| 2016 Q1 | 77.69 Billion IDR | -42.69% |
| 2016 Q3 | 139.93 Billion IDR | 48.86% |
| 2015 Q3 | 134.66 Billion IDR | 128.23% |
| 2015 FY | - IDR | 19.23% |
| 2015 Q1 | 79.09 Billion IDR | -38.53% |
| 2015 Q2 | 59 Billion IDR | -25.4% |
| 2015 Q4 | 135.57 Billion IDR | 0.68% |
| 2014 Q4 | 128.67 Billion IDR | 8.15% |
| 2014 FY | - IDR | 16.53% |
| 2014 Q1 | 21.71 Billion IDR | -81.39% |
| 2014 Q3 | 118.98 Billion IDR | 56.27% |
| 2014 Q2 | 76.13 Billion IDR | 250.71% |
| 2013 Q1 | 32.19 Billion IDR | -56.71% |
| 2013 Q3 | 112.47 Billion IDR | 245.18% |
| 2013 Q4 | 116.63 Billion IDR | 3.69% |
| 2013 FY | - IDR | -2.32% |
| 2013 Q2 | 32.58 Billion IDR | 1.23% |
| 2012 Q3 | 95.14 Billion IDR | 24.75% |
| 2012 Q4 | 74.35 Billion IDR | -21.85% |
| 2012 Q1 | 45.47 Billion IDR | 19.14% |
| 2012 Q2 | 76.26 Billion IDR | 67.72% |
| 2012 FY | - IDR | 35.53% |
| 2011 Q2 | 28.3 Billion IDR | -20.32% |
| 2011 Q3 | 120.01 Billion IDR | 324.07% |
| 2011 Q4 | 38.16 Billion IDR | -68.2% |
| 2011 FY | - IDR | 51.85% |
| 2011 Q1 | 35.52 Billion IDR | 0.0% |
| 2010 FY | - IDR | 46.68% |
| 2009 FY | - IDR | 1.39% |
| 2008 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 1081.16 Billion IDR | 213.178% |
| PT Itama Ranoraya Tbk | 32.71 Billion IDR | 3840.122% |
| PT Millennium Pharmacon International Tbk | 124.5 Billion IDR | 1082.786% |
| PT Soho Global Health Tbk | 538.94 Billion IDR | 327.045% |